Trials / Sponsors / Adlai Nortye Biopharma Co., Ltd.

Adlai Nortye Biopharma Co., Ltd.

Industry · 8 registered clinical trials — 2 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS M Solid Tumors (Phase 1), RAS Mutation	Phase 1	2026-01-28
Suspended	AN0025 and Chemoradiotherapy Combination in Esophageal Cancer Esophageal Cancer	Phase 1	2022-01-18
Completed	Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer Advanced or Metastatic Breast Cancer	Phase 1	2021-10-11
Recruiting	First in Human, Dose Escalation Study of AN4005 Advanced Solid Tumor, Advanced Lymphoma	Phase 1	2021-09-27
Completed	Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors Locally Advanced Solid Tumor	Phase 1	2021-09-07
Completed	The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC Head and Neck Cancer	Phase 3	2020-12-12
Active Not Recruiting	AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous, Urothelial Carcinoma of the Bladder	Phase 1	2020-08-20
Completed	Preoperative Radiotherapy and E7046 in Rectum Cancer Neoadjuvant Therapy in Rectal Cancer	Phase 1	2017-05-17